Showing results (361-370 of 407) with videos related to

Sort By:
Pageof 41
Nature|July 15, 2016
Early myeloid lineage choice is not initiated by random PU.1 to GATA1 protein ratiosPhilipp S Hoppe, Michael Schwarzfischer, Dirk Loeffler, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
The Journal of Pathology|October 15, 2013
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cellsYihui Fan, Ningling Ge, Xiaosong Wang, et al.
Cell Metabolism|May 8, 2012
Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathyBrian York, Erin L Reineke, Jørn V Sagen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2026
Rat somatic genome editing enables ER+ breast cancer modelingWen Bu, Tobie D Lee, Meenakshi Anurag, et al.
Scientific Data|November 2, 2019
The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathwaysScott A Ochsner, David Abraham, Kirt Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Huizhong Hu, Yen-Chao Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J Creighton, Xiaoxian Li, Melissa Landis, et al.
Cancers|February 25, 2023
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well ToleratedAlexandra McLean Stevens, Eric S Schafer, Minhua Li, et al.
Pageof 41